These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 29480485)

  • 1. Studying the Role of AMPK in Cardiac Hypertrophy and Protein Synthesis.
    Mailleux F; Beauloye C; Balligand JL; Horman S; Bertrand L
    Methods Mol Biol; 2018; 1732():321-342. PubMed ID: 29480485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term activation of adenosine monophosphate-activated protein kinase attenuates pressure-overload-induced cardiac hypertrophy.
    Li HL; Yin R; Chen D; Liu D; Wang D; Yang Q; Dong YG
    J Cell Biochem; 2007 Apr; 100(5):1086-99. PubMed ID: 17266062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AMPK activation enhances PPARα activity to inhibit cardiac hypertrophy via ERK1/2 MAPK signaling pathway.
    Meng R; Pei Z; Zhang A; Zhou Y; Cai X; Chen B; Liu G; Mai W; Wei J; Dong Y
    Arch Biochem Biophys; 2011 Jul; 511(1-2):1-7. PubMed ID: 21530483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte.
    Chan AY; Soltys CL; Young ME; Proud CG; Dyck JR
    J Biol Chem; 2004 Jul; 279(31):32771-9. PubMed ID: 15159410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation.
    Gélinas R; Mailleux F; Dontaine J; Bultot L; Demeulder B; Ginion A; Daskalopoulos EP; Esfahani H; Dubois-Deruy E; Lauzier B; Gauthier C; Olson AK; Bouchard B; Des Rosiers C; Viollet B; Sakamoto K; Balligand JL; Vanoverschelde JL; Beauloye C; Horman S; Bertrand L
    Nat Commun; 2018 Jan; 9(1):374. PubMed ID: 29371602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AMPK Signaling Involvement for the Repression of the IL-1β-Induced Group IIA Secretory Phospholipase A2 Expression in VSMCs.
    El Hadri K; Denoyelle C; Ravaux L; Viollet B; Foretz M; Friguet B; Rouis M; Raymondjean M
    PLoS One; 2015; 10(7):e0132498. PubMed ID: 26162096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR.
    Sakamoto K; Göransson O; Hardie DG; Alessi DR
    Am J Physiol Endocrinol Metab; 2004 Aug; 287(2):E310-7. PubMed ID: 15068958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenosine monophosphate-activated protein kinase attenuates cardiomyocyte hypertrophy through regulation of FOXO3a/MAFbx signaling pathway.
    Chen B; Wu Q; Xiong Z; Ma Y; Yu S; Chen D; Huang S; Dong Y
    Acta Biochim Biophys Sin (Shanghai); 2016 Sep; 48(9):827-32. PubMed ID: 27521792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-like growth factor I receptor signaling is required for exercise-induced cardiac hypertrophy.
    Kim J; Wende AR; Sena S; Theobald HA; Soto J; Sloan C; Wayment BE; Litwin SE; Holzenberger M; LeRoith D; Abel ED
    Mol Endocrinol; 2008 Nov; 22(11):2531-43. PubMed ID: 18801929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet effect of AMP-activated protein kinase activator and its potentiation by the phosphodiesterase inhibitor dipyridamole.
    Liu Y; Oh SJ; Chang KH; Kim YG; Lee MY
    Biochem Pharmacol; 2013 Oct; 86(7):914-25. PubMed ID: 23876340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldolase promotes the development of cardiac hypertrophy by targeting AMPK signaling.
    Li Y; Zhang D; Kong L; Shi H; Tian X; Gao L; Liu Y; Wu L; Du B; Huang Z; Liang C; Wang Z; Yao R; Zhang Y
    Exp Cell Res; 2018 Sep; 370(1):78-86. PubMed ID: 29902536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the atypical protein kinase Czeta in regulation of 5'-AMP-activated protein kinase in cardiac and skeletal muscle.
    Ussher JR; Jaswal JS; Wagg CS; Armstrong HE; Lopaschuk DG; Keung W; Lopaschuk GD
    Am J Physiol Endocrinol Metab; 2009 Aug; 297(2):E349-57. PubMed ID: 19625676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of AMPK inhibits cardiomyocyte hypertrophy by modulating of the FOXO1/MuRF1 signaling pathway in vitro.
    Chen BL; Ma YD; Meng RS; Xiong ZJ; Wang HN; Zeng JY; Liu C; Dong YG
    Acta Pharmacol Sin; 2010 Jul; 31(7):798-804. PubMed ID: 20581852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time course changes in signaling pathways and protein synthesis in C2C12 myotubes following AMPK activation by AICAR.
    Williamson DL; Bolster DR; Kimball SR; Jefferson LS
    Am J Physiol Endocrinol Metab; 2006 Jul; 291(1):E80-9. PubMed ID: 16760336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AMP-activated protein kinase protects cardiomyocytes against hypoxic injury through attenuation of endoplasmic reticulum stress.
    Terai K; Hiramoto Y; Masaki M; Sugiyama S; Kuroda T; Hori M; Kawase I; Hirota H
    Mol Cell Biol; 2005 Nov; 25(21):9554-75. PubMed ID: 16227605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transient activation of AMPK preceding left ventricular pressure overload reduces adverse remodeling and preserves left ventricular function.
    Nam DH; Kim E; Benham A; Park HK; Soibam B; Taffet GE; Kaelber JT; Suh JH; Taegtmeyer H; Entman ML; Reineke EL
    FASEB J; 2019 Jan; 33(1):711-721. PubMed ID: 30024790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AICAR induces cyclooxygenase-2 expression through AMP-activated protein kinase-transforming growth factor-beta-activated kinase 1-p38 mitogen-activated protein kinase signaling pathway.
    Chang MY; Ho FM; Wang JS; Kang HC; Chang Y; Ye ZX; Lin WW
    Biochem Pharmacol; 2010 Oct; 80(8):1210-20. PubMed ID: 20615388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential AMPK phosphorylation sites associated with phenylephrine vs. antihypertrophic effects of adenosine agonists in neonatal rat ventricular myocytes.
    Pang T; Rajapurohitam V; Cook MA; Karmazyn M
    Am J Physiol Heart Circ Physiol; 2010 May; 298(5):H1382-90. PubMed ID: 20190100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-hypertrophic effect of NHE-1 inhibition involves GSK-3beta-dependent attenuation of mitochondrial dysfunction.
    Javadov S; Rajapurohitam V; Kilić A; Zeidan A; Choi A; Karmazyn M
    J Mol Cell Cardiol; 2009 Jun; 46(6):998-1007. PubMed ID: 19318234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of AMP-activated protein kinase activators in antiproliferative multi-drug pituitary tumour therapies: effects of combined treatments with compounds affecting the mTOR-p70S6 kinase axis in cultured pituitary tumour cells.
    Tulipano G; Faggi L; Cacciamali A; Spinello M; Cocchi D; Giustina A
    J Neuroendocrinol; 2015 Jan; 27(1):20-32. PubMed ID: 25323047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.